PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especi...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 8, 2016
|
| In: |
Breast care
Year: 2016, Jahrgang: 11, Heft: 6, Pages: 385-390 |
| ISSN: | 1661-3805 |
| DOI: | 10.1159/000453569 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000453569 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/453569 
|
| Verfasserangaben: | Andreas D. Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y. Brucker |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1696940044 | ||
| 003 | DE-627 | ||
| 005 | 20230427121945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200430s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000453569 |2 doi | |
| 035 | |a (DE-627)1696940044 | ||
| 035 | |a (DE-599)KXP1696940044 | ||
| 035 | |a (OCoLC)1341317832 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hartkopf, Andreas |d 1979- |e VerfasserIn |0 (DE-588)139124101 |0 (DE-627)703216279 |0 (DE-576)309901596 |4 aut | |
| 245 | 1 | 0 | |a PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer |c Andreas D. Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y. Brucker |
| 264 | 1 | |c December 8, 2016 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.04.2020 | ||
| 520 | |a Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer. | ||
| 700 | 1 | |a Taran, Florin-Andrei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, Markus |d 1980- |e VerfasserIn |0 (DE-588)134044827 |0 (DE-627)692043934 |0 (DE-576)27468327X |4 aut | |
| 700 | 1 | |a Walter, Christina B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krämer, Bernhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grischke, Eva-Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brucker, Sara Y. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast care |d Basel : Karger, 2006 |g 11(2016), 6, Seite 385-390 |h Online-Ressource |w (DE-627)501078142 |w (DE-600)2205941-6 |w (DE-576)276272617 |x 1661-3805 |7 nnas |a PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer |
| 773 | 1 | 8 | |g volume:11 |g year:2016 |g number:6 |g pages:385-390 |g extent:6 |a PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000453569 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/453569 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200430 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 134044827 |a Wallwiener, Markus |m 134044827:Wallwiener, Markus |d 910000 |d 910400 |e 910000PW134044827 |e 910400PW134044827 |k 0/910000/ |k 1/910000/910400/ |p 3 | ||
| 999 | |a KXP-PPN1696940044 |e 3646418117 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"6 S."}],"id":{"eki":["1696940044"],"doi":["10.1159/000453569"]},"title":[{"title_sort":"PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer","title":"PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"December 8, 2016","dateIssuedKey":"2016"}],"relHost":[{"recId":"501078142","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2205941-6"],"eki":["501078142"],"issn":["1661-3805"]},"title":[{"title_sort":"Breast care","subtitle":"multidisciplinary journal for research, diagnosis and therapy","title":"Breast care"}],"origin":[{"publisher":"Karger","dateIssuedDisp":"2006-","dateIssuedKey":"2006","publisherPlace":"Basel"}],"part":{"volume":"11","year":"2016","text":"11(2016), 6, Seite 385-390","issue":"6","extent":"6","pages":"385-390"},"language":["eng"],"note":["Gesehen am 04.04.2019"],"pubHistory":["1.2006 -"],"disp":"PD-1 and PD-L1 immune checkpoint blockade to treat breast cancerBreast care","type":{"bibl":"periodical","media":"Online-Ressource"}}],"name":{"displayForm":["Andreas D. Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y. Brucker"]},"language":["eng"],"note":["Gesehen am 30.04.2020"],"person":[{"family":"Hartkopf","role":"aut","given":"Andreas","display":"Hartkopf, Andreas"},{"given":"Florin-Andrei","display":"Taran, Florin-Andrei","family":"Taran","role":"aut"},{"role":"aut","family":"Wallwiener","display":"Wallwiener, Markus","given":"Markus"},{"display":"Walter, Christina B.","given":"Christina B.","role":"aut","family":"Walter"},{"display":"Krämer, Bernhard","given":"Bernhard","family":"Krämer","role":"aut"},{"family":"Grischke","role":"aut","given":"Eva-Maria","display":"Grischke, Eva-Maria"},{"display":"Brucker, Sara Y.","given":"Sara Y.","role":"aut","family":"Brucker"}],"recId":"1696940044"} | ||
| SRT | |a HARTKOPFANPD1ANDPDL18201 | ||